anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for making a drug for removing subcutaneous fat. That is ensured by using a composition containing: at least one phospholipid, at least one glycyrrhizic acid or a glycyrrhizic acid salt, and wherein total content of phospholipids and glycyrrhizic acid or its salts makes 2-80 wt % and a weight ratio of phospholipids and glycyrrhizic acid or its salts makes from 30:1 to 0.5:1. The composition can additionally contain additives. As phospholipid, the composition contains animal or herbal phosphatidylcholine. The composition can also contain glycyrrhizic acid or potassium, sodium, ammonium or magnesium salt of glycyrrhizic acid. As an additive, the composition contains sugar, particularly glucose, or maltose, and/or their derivatives, mannitol, sorbitol or lactose. The composition contains phosphatidylcholine in a total amount of 15 to 98 wt %, preferentially 30 to 98 wt %, more preferentially 50 to 98 wt %, especially preferentially 75 to 98 wt %, and most preferentially 75 to 90 wt % of total content of phospholipids. The composition is used in the dry form, preferentially in the form of lyophilisate prepared by freezing and drying, or in the form of a solution. The composition can contain physiologically acceptable solvents, including water, normal saline, glucose solution, such monohydric alcohols, as ethanol, 2-propanol, n-propanol, such polyatomic alcohols, as glycerol and/or propane diol, such polyglycols, as polyethylene glycol and/or Miglyol, glycerol, formal, dimethylisosorbitol, natural and synthetic oils and/or esters. Diseases of subcutaneous fatty tissue can be particularly related to local fat maldistribution. Fatty tissue tumour decomposition and reduction can be also solved. The drug can be presented in the form of cream, ointment, gel, hydrogel, lotion, paste, powder or solution. Undesired unaesthetic and pathological local fat maldistribution involve lipoedema, adipose growth, abdominal adiposis, cellulites, pseudogynecomasty, "buffalo hump" in HIV-infected patients, panniculitis or nonspecific subcutaneous fat deposition. The preparation is administered by subcutaneous, intra-abdominal, intramuscular or intravenous injection. The administration is implemented by a method specified in a group consisting of ioophoresis, electroporetion and phonophoresis.EFFECT: described invention is successfully used for the above purposes.17 cl, 11 ex, 7 tbl, 11 dwg
PROBLEM TO BE SOLVED: To provide a hair dye composition capable of well dyeing the hair, without dyeing the scalp when used in dyeing operation. SOLUTION: This hair dye composition satisfies the following requisites: the difference between a melting point of the solid part of a mixture comprising 3 pts.wt. of (A) a model composition for horny layer intercellular lipid and 25 pts.wt. of (B) a hair dye base material not containing the dye and a melting point of the solid part of a mixture comprising 3 pts.wt. of the model composition for horny layer intercellular lipid (A) and 25 pts.wt. of distilled water is not greater than 10 deg.C;  and the hair dye base material (B) contained in the composition has such a property as to give a color-difference value of >=70 to the goat hair, when the goat hair is dyed at 30 deg.C for 10 min in a bath ratio of 1 (the goat hair) to 50 (the hair dye) by the use of a dye solution which is obtained by adding Red No.105 to the hair dye base material (B) so that the solution contains 0.1 wt.% of the Red No.105.
FIELD: veterinary science, medicine. SUBSTANCE: the present innovation deals with obtaining calcium-containing preparations. The method to obtain the preparation deals with the fact that the second mother liquor of calcium gluconate production 15-25 weight%, after separating acetone at room temperature should be additionally supplemented with vitamin D 3  as hydrovit and conservant as sorbic acid. The mixture obtained should be heated up to 40 C, kept at the same temperature for 30 min. As a result, preparation is obtained at the following ratio of ingredients, weight%: vitamin D 3  as hydrovit 40000 IU/g 0.01-0.03, conservant as sorbic acid 0.05-0.15, the second mother liquor at microbial production of calcium gluconate 15-25 weight% after separating acetone the rest. Calcium-containing preparation and method for its obtaining provide high degree of digestibility, balancing by preparation's composition, reasonable price to perform prophylactic measures. EFFECT: prolonged expiry terms. 2 cl, 7 ex, 2 tbl
Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 10 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
The inner surface of the crowns was treated with 'G-Multi Primer' using a brush and subsequently air-dried. The surfaces of the prepared teeth were treated with 37% orthophosphoric acid. The tooth surfaces were rinsed with an air-water spray to remove the acid from the surfaces. After the etching process, the 'G-Premio Bond' was applied to the teeth surfaces with a brush, rubbed for 10 seconds, and then air-dried for five seconds. Then the teeth were exposed to halogen/LED light (800-1200mW/cm2) (Valo Cordless, Ultradent) for 10 seconds. G-CEM Linkforce (GC, USA) resin cement was gently applied to crowns, and then crowns were pressed onto the prepared teeth with finger pressure.
BACKGROUND: Oligosaccharides have been demonstrated as promoters for enhancing plant growth across several crops by elevating their secondary metabolites. However, the exploration of employing diverse oligosaccharides for qualitative trait improvements in cauliflower largely unknown. This study was intended to uncover the unexplored potential, evaluating the stimulatory effects of three oligosaccharides on cauliflower's curd and seed production.
METHODS: Two experiments were initiated in the early (15 September) and mid-season (15 October). Four treatments were implemented, encompassing a control (water) alongside chitosan oligosaccharide (COS 50 mg.L-1) with a degree of polymerization (DP) 2-10, oligo galacturonic acid (OGA 50 mg.L-1) with DP 2-10 and alginate oligosaccharide (AOS 50 mg.L-1) with DP 2-7.
RESULTS: Oligosaccharides accelerated plant height (4-17.6%), leaf number (17-43%), curd (5-14.55%), and seed yield (17.8-64.5%) in both early and mid-season compared to control. These enhancements were even more pronounced in the mid-season (7.6-17.6%, 21.37-43%, 7.27-14.55%, 25.89-64.5%) than in the early season. Additionally, three oligosaccharides demonstrated significant disease resistance against black rot in both seasons, outperforming the control. As a surprise, the early season experienced better growth parameters than the mid-season. However, performance patterns remained more or less consistent in both seasons under the same treatments. COS and OGA promoted plant biomass and curd yield by promoting Soil Plant Analysis Development (SPAD) value and phenol content. Meanwhile, AOS increased seed yield (56.8-64.5%) and elevated levels of chlorophyll, ascorbic acid, flavonoids, while decreasing levels of hydrogen per oxide (H2O2), malondialdehyde (MDA), half maximal inhibitory concentration (IC50), and disease index. The correlation matrix and principal component analysis (PCA) supported these relations and findings. Therefore, COS and OGA could be suggested for curd production and AOS for seed production in the early season, offering resistance to both biotic and abiotic stresses for cauliflower cultivation under field conditions.
The present invention relates to a polypeptide, or pharmaceutically acceptable salt thereof, comprising the formula PTH(1-X)/PTHrP(Y-36). Further, the present invention refers to a polypeptide which binds the PTH receptor and has a high affinity for the R 0  form of the PTH receptor and to a polypeptide having affinity for PTH RG and a low affinity for PTH R 0 . Moreover, the present invention includes to a pharmaceutical composition comprising such polypeptide. The present invention further relates to a polypeptide or a pharmaceutical composition of the present invention for use in a method for treating a disease or condition. Moreover, the present invention refers to a nucleic acid comprising a sequence encoding a polypeptide of the present invention, a vector comprising said nucleic acid, a cell comprising said vector and a method of making a polypeptide of the present invention. Finally, the present invention further relates to a method for determining whether a candidate compound is a long-acting agonist of a G protein coupled receptor (GPCR).
Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
Aty. Docket No.: H-KN-01921 WOI A remote monitoring system for monitoring a plurality of medical devices at a patient care or home care facility. The system includes a device integration server in communication with wireless relay modules for receiving data packets from the medical devices including an identifier and data for each medical device. The system also includes an outbound web server. The web server is configured to provide webpages including the data of the medical devices for display on first and second remote monitoring devices, subject to authentication of an associated data request from the monitoring device. Page 30
Marfan syndrome (MFS) is a rare genetic disease (1/5000) characterized by the association of ocular impairment, cardiovascular disease and musculoskeletal disease. Chronic fatigue and decreased physical endurance are almost constant complaints of patients with MFS (90% according to some studies), and have an impact on activities of daily living and quality of life. The fragility of the connective tissues and the muscle deficit, responsible for increased stress on the musculoskeletal system, may be involved in this symptomatology. This deficiency in muscle mass is already present in young children and worsens in adolescents and young adults, as researchers have shown in a clinical study carried out in the Toulouse MFS competence center. This muscle deficit may also explain, at least in part, the deficit in bone mass observed in children and adults.

In some chronic conditions, physical activity and training have been shown to be effective in improving muscle strength and functional abilities but also fatigue and quality of life. Investigators hypothesize that the implementation of a personalized exercise rehabilitation program (Personalized Training Program) in children and young adults with MFS, by improving muscle mass, physical endurance, muscle strength, bone mass and quality of life of these patients. In order to test this hypothesis, investigators wish to carry out an interventional, prospective, monocentric study for the first time in children and young adults (\<25 years old) presenting an MFS.
Methods and compositions for treating a subject at risk for or suffering from weight gain caused by an antipsychotic agent are disclosed. The methods comprise administering a cyclohexylpyrimidine Glucocorticoid Receptor Modulator (GRM), such as milrinone (cor 118335), to a patient who receives or has received or is expected to receive an antipsychotic, such as olanzapine, risperidone, clozapine, or other weight-inducing antipsychotic. GRM (e.g., micranol) can be administered orally. Administration of such GRMs with an antipsychotic may reduce body weight, or reduce the rate of weight gain, or prevent weight gain that would otherwise result from an antipsychotic alone. The method may reverse weight gain in patients who had previously been administered an antipsychotic. Such GRM administered with an antipsychotic may reduce insulin resistance or blood levels of liver enzymes (AST, ALT), triglycerides, or insulin, or reduce an increase thereof, or prevent an increase thereof, or reverse an increase thereof.
Patients were treated in 1-2 sessions within a period of 7 days, with a minimum of 90 minutes per session. Implant-supported restorations were unscrewed and modified if they were not cleansable. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement . Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was performed. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Systemic antibiotics, when prescribed, were metronidazole or azithromycin.
964,367. Spraying-drying foods, blood plasma &c. BIRS BRIT A.G. Feb 1, 1962 [Feb. 6, 1961], No. 3943/62. Heading A2D. [Also in Divisions B1 and B2] In a method of producing instantly soluble or dispersable dried powders from liquid materials such as milk, butter, fruit juices and blood plasma, by spraying the liquid down a tower against an ascending current of drying gas, e.g. air, liquid drops of uniform size are produced in the tower by feeding the liquid through tube 1 on to baffle 3 which distributes it on to the inner wall of frusto-conical member 4 which is rotated at 3000 to 100,000 revolutions per minute whereby the liquid spreads out as a film on the inner wall and uniform drops become detached from the lower edge. The diameter of the lower end of element 4 is 100 to 200 mm. If necessary, three or more frusto-conical members may be provided in the upper part of the tower. The baffle may be impermeable or perforated. The height of the tower is preferably 50 to 100 m. The drying temperature should not exceed 60‹C., and the duration of contact of liquid drops and gas is preferably 10 to 200 seconds. Drop sizes of 5 to 2000 u, preferably about 200 u, may be obtained by adjusting the conditions of operation. Liquid drops in the form of an emulsion can be obtained by introducing air inside the frusto-conical member. Specification 886,533 is referred to.
OBJECTIVES: To characterize the clinical features and to identify the predictors of recurrence of histiocytic necrotizing lymphadenitis (HNL) in Chinese children.
STUDY DESIGN: This study retrospectively analyzed the clinical characteristics, laboratory and pathological findings, and recurrence status of children diagnosed with HNL at a single center in China from January 2018 to May 2023. Logistic regression analysis was employed to identify predictors of HNL recurrence.
RESULTS: 181 Chinese children with histopathologically confirmed HNL were enrolled (121 males and 60 females). The mean age was 9.3 ± 2.9 years. The most prominent clinical features were fever (98.9%) and cervical lymphadenopathy (98.3%). Aseptic meningitis was the most frequent complication (38.5%), while hemophagocytic lymphohistiocytosis and autoimmune disease were rare (1.7% and 1.2%, respectively). Recurrence occurred in 12.7% of patients. Erythrocyte sedimentation rate (> 30 mm/h) was the significant predictors of HNL recurrence, with odds ratios of 6.107, respectively.
CONCLUSION: Our study demonstrates that fever and cervical lymphadenopathy are the most frequent clinical manifestations of HNL in Chinese children, which often coexist with aseptic meningitis. HNL patients with risk factors require follow-up for recurrence.
PROBLEM TO BE SOLVED: To obtain a compound having excellent antiemetic activity based on its potent serotonin S3 (5HT3 ) and dopamine D2 antagonistic action, thus useful for treating and preventing various digestive organ symptoms involved in various diseases and therapeutic methods. SOLUTION: This compound, a cyclic amine derivative, is expressed by formula I  X is CH or N; Y is (CH2 )n , O, etc.; (n) is 1, 2 or 3; R1 is an alkyl, R2 is an alkoxyl; R3 is amino, a monoalkylamino, etc.; R4 is a halogen; wavy line means the steric configuration of the bound carbon atoms represents RS, R or S}, e.g. 5-chloro-N-(1-ethyl-1H-hexahydroazepin-3-yl)-2-methoxy-4- methylaminobenzamide. The compound of formula I is obtained by reaction of a compound of formula II with a compound of formula II in a solvent such as benzene pref. at about -10 to 150 deg.C.
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in transcription prevention and persistent cosmetic effect without adverse effect on the skin feeling by formulating a specific silicone elastomer, an adhesive resin and a solid oil. SOLUTION: Crushed silicone elastomer, an adhesive resin and a solid oil, in addition, a powder are formulated to produce this cosmetic. The crushed silicone elastomer is prepared by wet-crushing a silicone elastomer in a solvent or an oil. The adhesive resin is a trimethyl-siloxysilicic acid-acryl-silicone graft copolymer. These silicone elastomer and adhesive resin are preferably swollen with or dissolved in a volatile silicone or a silicone oil. As a solid oil, are cited cacao fat, lauryl alcohol or the like. The powder is, for example, a nylon powder, silica or the like. The amounts of the crushed silicone elastomer, the adhesive resin, the solid component and the powder are preferably (1-40):40:(0.1-40):(0.1-50) pts.wt. per 100 pts.wt. of the cosmetic, respectively.
The preservation of the left colic artery (LCA) during rectal cancer resection remains a topic of controversy, and there is a notable absence of robust evidence regarding the outcomes associated with LCA preservation. And the advantages of robotic-assisted laparoscopy (RAL) surgery in rectal resection remain uncertain. The objective of this study was to assess the influence of LCA preservation surgery and RAL surgery on intraoperative and postoperative complications of rectal cancer resection. Patients who underwent laparoscopic (LSC) or RAL with or without LCA preservation resection for rectal cancer between April 2020 and May 2023 were retrospectively assessed. The patients were categorized into two groups: low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA. A one-to-one propensity score-matched analysis was performed to decrease confounding. The primary outcome was operative findings, operative morbidity, and postoperative genitourinary function. A total of 612 patients were eligible for this study, and propensity score matching yielded 139 patients in each group. The blood loss of the LL group was significantly less than that of the HL group (54.42 ± 12.99 mL vs. 65.71 ± 7.37 mL, p<0.001). The urinary catheter withdrawal time in the LL group was significantly shorter than that in the HL group (4.87 ± 2.04 d vs. 6.06 ± 2.43d, p<0.001). Anastomotic leakage in the LL group was significantly lower than that in HL group (1.44% vs. 7.91%, p = 0.011). The rate of urinary dysfunction and sexual dysfunction in LL group is both significantly lower than HL group. Blood loss and number of harvested lymph nodes (LNs) of both RAL subgroups in LL and HL groups were significantly more than that in LSC subgroups. The anastomotic leakage in the RAL subgroup of HL group was significantly lower than that in LSC subgroup (0% vs. 14.89%, p = 0.018). LCA preservation surgery for rectal cancer may help reduce the blood loss, urinary catheter withdrawal time, the rate of anastomotic leakage and ileus, and postoperative genitourinary function outcomes. RAL can reduce the probability of blood loss and improve harvest LNs in patients with rectal cancer.
INTRODUCTION: Neck pain is one of the most common complaints in clinical practice and can be caused by a wide variety of conditions. While cervical spine surgery is a well-accepted option for radicular pain and myelopathy, surgery for isolated neck pain is controversial. The identification of the source of pain is challenging and subtle, and misdiagnosis can lead to inappropriate treatment. MATERIALS AND METHODS AND RESULTS: We conducted a thorough literature review to discuss and compare different causes of neck pain. We then supplemented the literature with our senior author's expert analysis of treating cervical spine pathology.
CONCLUSIONS: This study provides an in-depth discussion of neck pain and its various presentations, as well as providing insight into treatment strategies and diagnostic pearls that may prevent mistreatment of cervical spine pathology.
The invention discloses externally used cream for treating beriberi. The cream comprises the following active pharmaceutical ingredients: 20-30g of common cnidium fruit, 15-25g of purslane herb, 10-20g of doubleteeth pubescent angelica root, 5-15g of herba artemisiae scopariae, 10-15g of prepared nutgrass galingale rhizome, 10-20g of figwort root, 12-18g of grassleaf sweetflag rhizome, 12-18g of reed rhizome, 5-16g of rhizoma polygonati, 10-15g of golden larch bark, 5-10g of semen brassicae campestris, 5-10g of divaricate saposhnikovia root and 5-12g of plantain seed. A preparation method is characterized by grinding the active pharmaceutical ingredients, mixing the powder, adding medical vaseline and mixing the mixture into a cream preparation, thus obtaining the cream. During treatment, the cream is applied to the feet and the feet are rubbed gently so that the cream is absorbed. The cream is applied once a day, generally takes effect within three-five days and can cure beriberi after eight-ten days. The externally used cream totally treats 207 patients, cures 176 patients, has obvious effects on 22 patients, is ineffective in nine patients and has total effective rate of 95.7%. The externally used cream has good treatment effects, is cheap and easily-obtained in all the active pharmaceutical ingredients, is low in cost and is suitable for common ordinary patients.
Participants received up to 40 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) of CBD with food. Participants also received up to 150 mg/kg/day BID of vigabatrin with food.
OBJECTIVE: To review the efficacy of exercise treatments on chronic obstructive pulmonary disease (COPD).
DATA SOURCES: PubMed, Scopus, Science Direct, Ebscohost, SPORTDiscus, ProQuest, Web of Science.
REVIEW METHODS: A systematic review was performed to identify the relevant studies published from 2011 to 2023. Studies were selected using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 5170 articles were retrieved and assessed using the Physiotherapy Evidence Database (PEDro) scale. The risk of bias in individual studies was assessed with the Cochrane risk of bias tool.
RESULTS: A total of 38 eligible studies were included. Eight studies evaluated the effects of Tai Chi, followed by Liuzijue (five studies) and yoga (three studies). The duration of the exercise programmes ranged from 8 weeks to 3 years, and the frequency was between 2 and 7 times a week. Exercise sessions lasted between 20 and 90 min. Low-intensity exercise improved lung function after six months. Whole-body exercise improved dyspnea more than local exercise. Water-based exercise improved physical endurance more than land exercise, and quality of life was unaffected by long-term exercise.
CONCLUSION: This systematic review highlights the benefit of exercise treatments as a potential adjunct treatment for COPD patients.